Purpose: To evaluate the impact of the vitreoretinal interface architecture, in specific the angle between the posterior vitreous cortex and the internal limiting membrane, on vitreomacular traction (VMT) resolution in eyes treated with intravitreally injected ocriplasmin (Jetrea). Methods: Retrospective, multicenter cohort study and exploratory data analysis. Spectral domain optical coherence tomography assessments were performed before scheduled ocriplasmin injections. General (age and sex) as well as ocular variables (lens status, presence of epiretinal membrane formations, horizontal diameter of VMT, central retinal thickness, and in particular various prespecified angles between the posterior vitreous cortex and internal limiting membr...
Purpose: To report the clinical course of our first 7 consecutive patients treated with intravitreal...
Background: To evaluate the functional recovery of patients with symptomatic vitreomacular traction ...
Benedicte Lescrauwaet,1 Koenraad Blot,2 Timothy L Jackson3 1Xintera, Outcomes Research, Ghent, Belgi...
BACKGROUND AND OBJECTIVE: To determine early evolution of the vitreomacular interface and clinical e...
PURPOSE: To evaluate baseline features and morphologic changes of vitreoretinal adhesion and outer ...
Purpose: To compare the functional and morphologic outcome of patients with vitreomacular traction (...
PURPOSE: To evaluate the anatomical and functional outcomes with ocriplasmin in patients with vitreo...
PURPOSE: To evaluate the efficacy of a single intravitreal injection of ocriplasmin 125 μg across re...
This retrospective quality control study aimed at comparing resolution in patients treated with intr...
AbstractPurpose: To evaluate success with intravitreal injection of ocriplasmin in releasing symptom...
PURPOSE: To evaluate the real world clinical outcomes of intravitreal ocriplasmin in patients with v...
PURPOSE: The purpose is to evaluate functional changes after ocriplasmin injection to treat vitreoma...
The recent approval by the US Food and Drug Administration of ocriplasmin for the treatment of sympt...
To evaluate the real world clinical outcomes of intravitreal ocriplasmin in patients with vitreomacu...
PURPOSE To evaluate the effect of the vitreomacular interface (VMI) on treatment efficacy of intr...
Purpose: To report the clinical course of our first 7 consecutive patients treated with intravitreal...
Background: To evaluate the functional recovery of patients with symptomatic vitreomacular traction ...
Benedicte Lescrauwaet,1 Koenraad Blot,2 Timothy L Jackson3 1Xintera, Outcomes Research, Ghent, Belgi...
BACKGROUND AND OBJECTIVE: To determine early evolution of the vitreomacular interface and clinical e...
PURPOSE: To evaluate baseline features and morphologic changes of vitreoretinal adhesion and outer ...
Purpose: To compare the functional and morphologic outcome of patients with vitreomacular traction (...
PURPOSE: To evaluate the anatomical and functional outcomes with ocriplasmin in patients with vitreo...
PURPOSE: To evaluate the efficacy of a single intravitreal injection of ocriplasmin 125 μg across re...
This retrospective quality control study aimed at comparing resolution in patients treated with intr...
AbstractPurpose: To evaluate success with intravitreal injection of ocriplasmin in releasing symptom...
PURPOSE: To evaluate the real world clinical outcomes of intravitreal ocriplasmin in patients with v...
PURPOSE: The purpose is to evaluate functional changes after ocriplasmin injection to treat vitreoma...
The recent approval by the US Food and Drug Administration of ocriplasmin for the treatment of sympt...
To evaluate the real world clinical outcomes of intravitreal ocriplasmin in patients with vitreomacu...
PURPOSE To evaluate the effect of the vitreomacular interface (VMI) on treatment efficacy of intr...
Purpose: To report the clinical course of our first 7 consecutive patients treated with intravitreal...
Background: To evaluate the functional recovery of patients with symptomatic vitreomacular traction ...
Benedicte Lescrauwaet,1 Koenraad Blot,2 Timothy L Jackson3 1Xintera, Outcomes Research, Ghent, Belgi...